Literature DB >> 1929309

Treatment of experimental cryptococcosis with SCH 39304 and fluconazole.

R Negroni1, M R Costa, J L Finquelievich, C Iovannitti, I Agorio, I N Tiraboschi, D Loebenberg.   

Abstract

The efficacy of two triazoles, SCH 39304 and fluconazole, in the treatment of disseminated cryptococcosis in Wistar rats was determined. A total of 160 rats were inoculated intracardiacally with 2 x 10(5) cells of Cryptococcus neoformans. Both drugs were administered by gavage once daily, at three doses (8, 16, and 32 mg/kg/day). Two treatment schedules were followed: (i) treatment began 1 week after infection and continued for 3 weeks and (ii) prophylaxis treatment began 3 days before infection and continued an additional 3 weeks. Evaluation was based on (i) macroscopic examination of lungs, (ii) microscopic examination of brains and lungs, (iii) histopathology of brains and lungs, and (iv) determination of number of CFU in brains. The number of CFU was the best measure of activity. SCH 39304 was more active than fluconazole in both regimens, and, prophylactically, SCH 39304 was able to achieve biological cures.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1929309      PMCID: PMC245190          DOI: 10.1128/AAC.35.7.1460

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  12 in total

1.  Efficacy of SCH39304 in murine cryptococcosis.

Authors:  B I Restrepo; J Ahrens; J R Graybill
Journal:  Antimicrob Agents Chemother       Date:  1989-08       Impact factor: 5.191

2.  Treatment of experimental cryptococcal meningitis and disseminated candidiasis with SCH39304.

Authors:  J R Perfect; K A Wright; M M Hobbs; D T Durack
Journal:  Antimicrob Agents Chemother       Date:  1989-10       Impact factor: 5.191

3.  Experience with itraconazole in deep mycoses in northern Italy.

Authors:  M A Viviani; A M Tortorano; R Woenstenborghs; G Cauwenbergh
Journal:  Mykosen       Date:  1987-05

4.  Cryptococcal meningitis in the acquired immunodeficiency syndrome (AIDS): successful treatment with fluconazole after failure of amphotericin B.

Authors:  W R Byrne; C P Wajszczuk
Journal:  Ann Intern Med       Date:  1988-03       Impact factor: 25.391

Review 5.  AIDS and the mycoses.

Authors:  A M Macher; M L De Vinatea; S M Tuur; P Angritt
Journal:  Infect Dis Clin North Am       Date:  1988-12       Impact factor: 5.982

6.  Mycological-diagnostic assessment of the efficacy of amphotericin B + flucytosine to control Cryptococcus neoformans in AIDS patients.

Authors:  F Staib; M Seibold
Journal:  Mycoses       Date:  1988-04       Impact factor: 4.377

7.  A comparison of amphotericin B alone and combined with flucytosine in the treatment of cryptoccal meningitis.

Authors:  J E Bennett; W E Dismukes; R J Duma; G Medoff; M A Sande; H Gallis; J Leonard; B T Fields; M Bradshaw; H Haywood; Z A McGee; T R Cate; C G Cobbs; J F Warner; D W Alling
Journal:  N Engl J Med       Date:  1979-07-19       Impact factor: 91.245

8.  [Experimental subacute cryptococcosis in Wistar rats].

Authors:  R Negroni; J L Finquelievich
Journal:  Medicina (B Aires)       Date:  1987       Impact factor: 0.653

9.  Treatment of experimental sub-acute cryptococcosis in the Wistar rat.

Authors:  J L Finquelievich; R Negroni; A J Bava; C Iovannitti
Journal:  Medicina (B Aires)       Date:  1988       Impact factor: 0.653

10.  Cryptococcosis in the acquired immunodeficiency syndrome.

Authors:  J A Kovacs; A A Kovacs; M Polis; W C Wright; V J Gill; C U Tuazon; E P Gelmann; H C Lane; R Longfield; G Overturf
Journal:  Ann Intern Med       Date:  1985-10       Impact factor: 25.391

View more
  2 in total

1.  Pathogenesis of pulmonary Cryptococcus neoformans infection in the rat.

Authors:  D Goldman; S C Lee; A Casadevall
Journal:  Infect Immun       Date:  1994-11       Impact factor: 3.441

2.  Effect of amphotericin B on the lipids of five different strains of Cryptococcus neoformans.

Authors:  S P Franzot; J S Hamdan
Journal:  Mycopathologia       Date:  1994-11       Impact factor: 2.574

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.